, and plasma somatomedin C concentrations were 1*0 (0-2) U/ml (n=8) and 2*1 (0.3) U/ml (n=16) in groups 1 and 2, respectively. The time between onset and diagnosis of secondary sexual characteristics was about one year in both groups. After two years' follow up the untreated patients in group 1 had maintained their predicted final height. These changes were in contrast to those observed at first examination in patients in group 2 who had a mean (SD) predicted final height of -1.3 (0.2) and a mean bone age advance of 3*0 (0.2) years. These data show that bone age advance to chronological age, and plasma somatomedin C concentrations measured at initial evaluation are helpful in identifying less severe and potentially slow progressing forms of central precocious puberty.
premature increase in the secretion of sex hormones that leads to acceleration of their growth rate. At the same time excessive progression of bone age may lead to short adult stature. The course of sexual precocity is variable, however, and in some cases normal growth continues with no reduction in predicted final height.' This clinical heterogeneity may partly explain the difficulty that has been encountered in establishing the effectiveness of treatment with cyproterone acetate2 or medroxyprogesterone. 3 More recently drugs such as luteinising hormone releasing hormone analogues have been shown to suppress gonadotrophin secretion and gonadal activity completely. Data from short term trials have already shown that there is an increase in the predicted final height. 8 We have studied the spontaneous course of precocious puberty according to its initial presentation, to evaluate the early use of luteinising hormone releasing hormone analogues.
Patients and methods
Thirty six girls with idiopathic precocious puberty who had been regularly followed up in the paediatric endocrinology unit were assigned to this study.
Informed consent was obtained from both them and their parents. The diagnostic criterion of precocious puberty was the occurrence of oestrogenic activity in association with the appearance of pubic hair before age of 8 Tables 1 and 2 show the clinical presentation and biological data of the two groups. The distribution of the breast development stage in relation to the bone age advance is shown in the figure. The mean chronological ages at the first evaluation and the mean time from the onset of sexual development were similar in both groups. By definition the mean bone age advance (expressed as bone age minus chronological age) was significantly lower in patients in group 1 (0.7 (0.1) years) compared with group 2 (3 (0.2) years) (p<0-001). The mean height gains during the year before the initial evaluation were similar in both groups, 7*8 (0-8) cm and 8-5 (0.4) cm, respectively. Patients of group 1 were, however, slightly but not significantly shorter, with a mean (SD) height score for chronological age of 1-6 (0-3) above the normal mean compared with 2-4 (0-2) for patients of group 2 (p<0-05). at first examination in 14 patients (stage 2), and the remaining three patients (cases 1, 3, and 4) developed pubic hair within eight months of diagnosis. All patients had pubic hair before the age of 8 years. Patients 7, 9, 11, and 16 had recurrent and spontaneously reversible spurts of breast development.
The initial biological data are shown in table 1. In group 1, the mean concentration of circulating oestradiol was 82 (30) pmolI (range 0-455). All except cases 6 and 15 had concentrations of less than 132 pmol/l. The mean vaginal maturation index was 16 (5) (range 0-50), mean luteinising hormone peak was 4.8 (1.4) IU/I (range 1-25), and the mean follicle stimulating hormone peak was 5-8 (0.9) IU/I (range 0.5-14). Eleven of 17 girls had no biochemical or cytological signs of oestrogen impregnation (oestradiol concentration <92 pmol/l and vaginal maturation index <35). In spite of the persistence of breast development, the two patients with the highest initial plasma oestradiol concentrations (cases 6 and 15) had prepubertal oestradiol concentrations and vaginal maturation indexes when re-evaluated six months later. Pelvic ultrasound examination did not disclose any ovarian cysts.
In contrast, most patients in group 2, whose bone age advance was at least two years, had overt clinical and biological signs of excessive oestrogen production when first seen. Their breast development was equal or above stage 3 in 14 cases. In the remaining four cases it was stage 2. In this group, the mean plasma concentration of oestradiol was 164 (21) pmol/l (range 37-404), the mean vaginal maturation index was 41 (4) (range 0-58), the mean peak luteinising hormone was 18 (4) IU/l (range 3-66), and the mean peak follicle stimulating hormone was 10-5 (1.5) IU/l (range 1-31). All the values in group 2 were significantly greater than the mean values in group 1 (table 1). They were thought to reflect a more mature hypothalamic gonadotrophin axis.
Plasma somatomedin C concentrations were measured in only eight patients from group 1 and 16 patients from group 2 (table 3). The mean plasma somatomedin C concentration of 1*0 (0.2) U/ml (range 0.3-1.7) in group 1 was significantly lower than that of 2 1 (0-3) U/ml (range 0-8-4.7) in group 2 (p<001). These two groups of patients also differed significantly in their plasma oestradiol concentrations (33 (11) pmoL/l in group 1 and 154 (18) pmol/l in group 2, p<0-001). The growth rate was similar in the two groups, however, (7-8 (0.8) and 8-9 (0.4) cm in groups 1 and 2, resp,ctively). We found no correlation between plasma oestradiol concentration and growth rate or plasma somatomedin C concentrations, either within the groups or in the whole population.
GROWTH IN UNTREATED PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY AND LOW OESTROGEN ACTIVITY
The spontaneous growth and bone maturation in patients in group 1 were analysed after a two year follow up period to evaluate the effect of persistently low oestrogenic activity (table 2). After two (SD) value of 1-6 (0.4) compared with a similar initial value of 1*6 (0-3). The mean (SD) final height prediction in these patients remained unchanged (0-1 (0.3) ) from the initial value in the group of 12 patients evaluated at the time of diagnosis (0.4 (2-2)). Interestingly, among the four patients with the greatest progression of bone maturation, only one (case 5) had a low final height at 2*2 standard deviations below the normal mean.
The results for the patients in group 1 were also compared with the initial data for patients in group 2 at the time of diagnosis when precocious puberty had already accelerated bone maturation by more than -two years. The mean (SD) predicted final height of patients in group 2 was -1-3 (0-2) below the normal mean, a value significantly lower than that calculated for patients in group 1 (0-1 (0-3)) after a much longer period of spontaneous progression of the disease (p<0-01). This comparison indicates that, despite nearly three years exposure to low or variable oestrogen activity in group 1, growth had remained sufficient in relation to bone maturation to permit a satisfactory mean final height prediction. This had not been the case in patients in group 2 seen after an average period of only one year who presented with pronounced oestrogen activity and rapidly progressing bone maturation. Discussion The results of this study showed that mild forms of central precocious puberty in girls can be identified at the first examination. They seem to be characterised by a combination of low plasma oestradiol and somatomedin C, and normal or slightly advanced bone age at the time of diagnosis. We have shown that the course of the disease in these cases is also different from the usually severe forms of precocious puberty.
Bone maturation and height gain do not progress in parallel when sex hormones are secreted before puberty, and it is known that precocious puberty may accelerate epiphyseal fusion and lead to a reduction in final height. The In the present report, the plasma somatomedin C values were in the prepubertal range or slightly raised in girls with mild forms of precocious puberty, and pubertal in those with the severe form. A more complete evaluation of growth hormone secretion using spontaneous growth hormone profiles could not be performed in these patients, but in view of their plasma somatomedin C values it is possible that the growth hormone secretion in the mild form of precocious puberty did not increase to the extent seen in normal puberty during the Tanner P3 stage 20 27 These authors reported a significant acceleration of growth without a concomitant change in plasma somatomedin C. When low doses of ethinyloestradiol were used in these patients, growth rates increased without changes in bone maturation or plasma somatomedin C concentration. In the present study, a similar course of events occurred in the group of girls with less severe precocious puberty. In contrast, when pronounced oestrogen activity was present at first examination, its effect was predominant on bone maturation, leading to a reduced final height prediction. This was because the growth rate was not appropriate for bone age progression, in contrast to the group with moderate precocious puberty.
The spontaneous course of idiopathic precocious puberty in girls varies in presentation of symptoms and rate of progression: some cases show accelerated development while others may progress slowly or have totally regressive characteristics.1 The results of this study show that the lack of excessive progression of bone age and the plasma prepubertal somatomedin C values nine to 12 months after the onset of puberty are good indicators of moderate oestrogen activity. It is of interest that most of these cases of mild precocious puberty at time of diagnosis did not develop into severe and rapidly progressing precocious puberty. Furthermore, the age distribution did not differ between the groups. We suggest that girls with such moderate forms of precocious puberty be followed up for at least one year before deciding whether or not to have treatment with luteinising hormone releasing hormone analogue. Such treatment may be delayed as long as the final height prediction can be closely followed. Regression of pubertal signs may occur. If treatment is decided upon, it may be appropriate to re-evaluate the hypophyseal ovarian activity after two years of follow up to avoid unduly prolonged treatment. Probably all of these factors should be taken into consideration before committing a girl with central precocious puberty to treatment with the analogue.
In conclusion, an untreated group of girls with idiopathic central precocious puberty and moderate ovarian activity was followed for a period of two years. The data obtained at their first examination and in the course of their disease showed that bone maturation and plasma somatomedin C values are helpful in identifying the less severe and potentially slowly progressing forms of central precocious puberty. These cases might not require immediate treatment with the luteinising hormone releasing hormone analogue and a close follow up may be preferred before treatment to evaluate their natural course.
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